BX · News · 20261103N

Bivamelagon Loan Financing

Blackstone Inc. · 2026-11-03 · Importance null · Surprise null

Rhythm Pharmaceuticals and LG Chem amended their exclusive license agreement for investigational drug bivamelagon. The revised agreement provides for Rhythm to make $350 million of additional fixed payments over four years and replaces the prior low-to-mid-single-digit royalty structure with a 1% royalty on global net sales of its MC4R portfolio. Rhythm secured a five-year, $750 million term-loan facility led by KKR’s HealthCare Royalty and Blackstone to support the arrangement.

Key facts